Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cerevel Therapeutics Hldg Inc (NQ: CERE ) 43.45 +0.01 (+0.02%) Streaming Delayed Price Updated: 11:52 AM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 548,698 Open 43.50 Bid (Size) 43.45 (4) Ask (Size) 43.46 (2) Prev. Close 43.44 Today's Range 43.32 - 43.53 52wk Range 19.59 - 43.61 Shares Outstanding 8,830,700 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm June 18, 2024 From The Schall Law Firm Via Business Wire CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm June 11, 2024 From Kaskela Law LLC Via Business Wire Performance YTD +2.94% +2.94% 1 Month +4.90% +4.90% 3 Month +3.21% +3.21% 6 Month +3.18% +3.18% 1 Year +41.85% +41.85% More News Read More Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses June 05, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire 10 Health Care Stocks Whale Activity In Today's Session June 04, 2024 Via Benzinga Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses May 29, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire 1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? May 20, 2024 Via The Motley Fool Topics Intellectual Property Exposures Intellectual Property CERE Stock Earnings: Cerevel Therapeutics Hldg Misses EPS for Q2 2024 May 09, 2024 Via InvestorPlace Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study April 18, 2024 Via Benzinga Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug April 15, 2024 Via Investor's Business Daily Tuesday Talk: Big-Tech Under Attack March 26, 2024 Via Talk Markets Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? March 25, 2024 Via Benzinga 3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024 March 09, 2024 Via InvestorPlace Is AbbVie Stock a Buy Now? February 22, 2024 Via The Motley Fool This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space February 16, 2024 Via Benzinga UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst February 06, 2024 Via Benzinga AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall February 02, 2024 Via Benzinga AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures January 29, 2024 Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq – January 29, 2024 From Brodsky & Smith LLC Via GlobeNewswire ABBV: This Top Biotech Just Went On A Buying Spree January 25, 2024 Via Talk Markets 7 Dividend Aristocrats That Will Pay You for Years to Come January 22, 2024 Via InvestorPlace CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders January 08, 2024 From Halper Sadeh LLC Via Business Wire 5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday January 08, 2024 Via Benzinga Is AbbVie Stock a Buy Now? January 07, 2024 Via The Motley Fool Topics Intellectual Property Exposures Intellectual Property BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. January 04, 2024 From Brodsky & Smith LLC Via GlobeNewswire Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 December 29, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
